Skip to main content

home

OVERVIEW
Our unique Guangzhou-Israel Biotechnology Fund (GIBF) creates added value for Israeli, European and American companies looking to expand in China.

With years of life sciences expertise, private equity investment experience, local knowledge based on over a decade of activity in China, and numerous foreign companies already established in China, GIBF serves as an invaluable strategic investor and partner in China with a proven ability and track record of conducting multi-center clinical trials in top-tier Chinese hospitals, providing the resources and networks for securing successful NMPA submissions, commercializing products and developing manufacturing capacity to satisfy both local and global demand.

OUR STRATEGY
Enabling value creation by investing in Chinese subsidiaries of foreign companies active in the biomedical outside China
GIBF partners with selected companies from Israel, Europe and the USA to establish new JVs in the Chinese market, enabling the foreign companies to control and manage their new subsidiaries as the majority shareholders.
PORTFOLIO
Companies' Overview
Partnering with top-tier international life sciences companies offering innovative solutions to Chinese healthcare needs.

COMPANY

InMode (NASDAQ: INMD) (Exit)

SECTOR

Medical Device

COMPANY

G-Medical (NASDAQ: GMVD)

SECTOR

Medical Device

COMPANY

CarboFix

SECTOR

Medical Device
OUR PEOPLE
Meet Our Management
Where global leaders in life sciences meet local talents to achieve cross-border investments and companies' formation.
DR. YEHOSHUA(SHUKI) GLEITMAN
Founding Partner and Chairman
PROF. SHLOMO NOY
Founding Partner and Chief Medical Officer
AVNER LUSHI
Founding Partner and CEO
CARL GENG
Founding Partner and General Manager
Latest
News

VIEW ALL

Latest
News
Bioversys

BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office

(31 March, 2025) BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today, that the company was granted important patent claims in China for its BV100 technology.

投资组合向右箭头
silexion

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

(25 February, 2025) Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks. 

投资组合向右箭头
Bioversys

BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE

(11 February, 2025) BioVersys AG (SIX: BIOV) announced today that its BV500 NTM program has reached its second milestone, “identification of up to 5 Optimized Lead compounds”, under the CF AMR Syndicate Collaborative Discovery Programme (CDP) agreement. Supported by LifeArc funding, BioVersys is developing novel small molecules targeting difficult to treat non-tuberculous mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).

投资组合向右箭头